Tscan therapeutics appoints gavin macbeath, ph.d. as chief executive officer and as a member of the board of directors

Waltham, mass., may 24, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx) (tscan), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that its board of directors (the board) has appointed gavin macbeath, ph.d., as chief executive officer (ceo) of tscan and as a class i director of its board, each effective as of may 24, 2023. dr. macbeath, has been serving as acting ceo since march 2023. dr. macbeath will no longer serve as chief scientific and operating officer of the company, effective may 24, 2023.
TCRX Ratings Summary
TCRX Quant Ranking